With 1.66 million shares changed hands, the volume of the stock remained heavier than its average volume of 30910.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.98 whereas the lowest price it dropped to was $3.1. The 52-week range on CLGN shows that it touched its highest point at $5.89 and its lowest point at $1.55 during that stretch. It currently has a 1-year price target of $12.00. Beta for the stock currently stands at 0.88.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CLGN was up-trending over the past week, with a rise of 122.55%, but this was up by 104.97% over a month. Three-month performance surged to 29.71% while six-month performance rose 7.33%. The stock lost -25.57% in the past year, while it has gained 26.11% so far this year. A look at the trailing 12-month EPS for CLGN yields -1.21 with Next year EPS estimates of 0.01. For the next quarter, that number is -0.14. This implies an EPS growth rate of 78.62% for this year and 103.23% for next year. EPS is expected to grow by 47.48% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 8.32%.
Float and Shares Shorts:
At present, 11.45 million CLGN shares are outstanding with a float of 7.68 million shares on hand for trading. On 2025-04-30, short shares totaled 1314.0, which was 1.0 higher than short shares on 1743379200. In addition to Mr. Yehiel Tal as the firm’s CEO & Director, Mr. Eran Rotem CPA serves as its Deputy CEO & CFO.
Institutional Ownership:
Through their ownership of 0.12234 of CLGN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, CLGN reported revenue of $nan and operating income of $nan. The EBITDA in the recently reported quarter was $nan and diluted EPS was $nan.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CLGN analysts setting a high price target of 12.0 and a low target of 12.0, the average target price over the next 12 months is 12.0. Based on these targets, CLGN could surge 164.32% to reach the target high and rise by 164.32% to reach the target low. Reaching the average price target will result in a growth of 164.32% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.08 being high and -$1.08 being low. For CLGN, this leads to a yearly average estimate of -$1.08.
